Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas

Hoon K. Lee, Richard B. Wilder, Dan Jones, Chul S Ha, Barbara Pro, Maria A. Rodriguez, Jorge E. Romaguera, Fernando Cabanillas, Jose Rodriguez, James D. Cox

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

There is little information in the literature on outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. The purpose of this study was to analyze The University of Texas M.D. Anderson Cancer Center results in such patients. From 1985 to 1998, 39 patients with Stage I or II World Health Organization classification anaplastic large cell lymphoma (ALCL; n = 20), peripheral T-cell lymphoma, unspecified (PTCLu; n = 11), or nasal-type NK/T-cell lymphoma (NKTCL; n = 8) were treated using doxorubicin-based chemotherapy (median, 6 cycles) with (n = 24) or without (n = 15) radiotherapy (median dose, 40 Gy). Median age was 41 years. Median follow-up of surviving patients was 85 months. Even though patients who presented with bulky disease or who achieved less than a complete response to chemotherapy were the ones typically treated with combined modality therapy rather than chemotherapy alone, there was no significant difference in local control (5-year rates: 60 vs. 70%, p = 0.49), progression-free survival (5-year rates: 65 vs. 60%, p = 0.62), or overall survival (5-year rates: 74 vs. 67%, p = 0.47) between the groups treated with combined modality therapy and chemotherapy alone. Fifteen (38%) patients relapsed. Twelve relapses were limited to the initial site of disease; two involved the initial site and new sites, and one involved only new sites. Based on the significant risk of relapse at the initial site of disease, different approaches, including chemotherapy with concomitant radiotherapy to doses ≥45 Gy, warrant investigation.

Original languageEnglish (US)
Pages (from-to)1769-1775
Number of pages7
JournalLeukemia and Lymphoma
Volume43
Issue number9
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Peripheral T-Cell Lymphoma
Doxorubicin
Radiotherapy
Drug Therapy
Combined Modality Therapy
Anaplastic Large-Cell Lymphoma
Recurrence
T-Cell Lymphoma
Nose
Natural Killer Cells
Disease-Free Survival
Survival
Neoplasms

Keywords

  • Chemotherapy
  • Prognosis
  • Radiotherapy
  • T-cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. / Lee, Hoon K.; Wilder, Richard B.; Jones, Dan; Ha, Chul S; Pro, Barbara; Rodriguez, Maria A.; Romaguera, Jorge E.; Cabanillas, Fernando; Rodriguez, Jose; Cox, James D.

In: Leukemia and Lymphoma, Vol. 43, No. 9, 2002, p. 1769-1775.

Research output: Contribution to journalArticle

Lee, HK, Wilder, RB, Jones, D, Ha, CS, Pro, B, Rodriguez, MA, Romaguera, JE, Cabanillas, F, Rodriguez, J & Cox, JD 2002, 'Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas', Leukemia and Lymphoma, vol. 43, no. 9, pp. 1769-1775. https://doi.org/10.1080/1042819021000006277
Lee, Hoon K. ; Wilder, Richard B. ; Jones, Dan ; Ha, Chul S ; Pro, Barbara ; Rodriguez, Maria A. ; Romaguera, Jorge E. ; Cabanillas, Fernando ; Rodriguez, Jose ; Cox, James D. / Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. In: Leukemia and Lymphoma. 2002 ; Vol. 43, No. 9. pp. 1769-1775.
@article{ba9e8522532a414a8aba217897d239a2,
title = "Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas",
abstract = "There is little information in the literature on outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. The purpose of this study was to analyze The University of Texas M.D. Anderson Cancer Center results in such patients. From 1985 to 1998, 39 patients with Stage I or II World Health Organization classification anaplastic large cell lymphoma (ALCL; n = 20), peripheral T-cell lymphoma, unspecified (PTCLu; n = 11), or nasal-type NK/T-cell lymphoma (NKTCL; n = 8) were treated using doxorubicin-based chemotherapy (median, 6 cycles) with (n = 24) or without (n = 15) radiotherapy (median dose, 40 Gy). Median age was 41 years. Median follow-up of surviving patients was 85 months. Even though patients who presented with bulky disease or who achieved less than a complete response to chemotherapy were the ones typically treated with combined modality therapy rather than chemotherapy alone, there was no significant difference in local control (5-year rates: 60 vs. 70{\%}, p = 0.49), progression-free survival (5-year rates: 65 vs. 60{\%}, p = 0.62), or overall survival (5-year rates: 74 vs. 67{\%}, p = 0.47) between the groups treated with combined modality therapy and chemotherapy alone. Fifteen (38{\%}) patients relapsed. Twelve relapses were limited to the initial site of disease; two involved the initial site and new sites, and one involved only new sites. Based on the significant risk of relapse at the initial site of disease, different approaches, including chemotherapy with concomitant radiotherapy to doses ≥45 Gy, warrant investigation.",
keywords = "Chemotherapy, Prognosis, Radiotherapy, T-cell lymphoma",
author = "Lee, {Hoon K.} and Wilder, {Richard B.} and Dan Jones and Ha, {Chul S} and Barbara Pro and Rodriguez, {Maria A.} and Romaguera, {Jorge E.} and Fernando Cabanillas and Jose Rodriguez and Cox, {James D.}",
year = "2002",
doi = "10.1080/1042819021000006277",
language = "English (US)",
volume = "43",
pages = "1769--1775",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas

AU - Lee, Hoon K.

AU - Wilder, Richard B.

AU - Jones, Dan

AU - Ha, Chul S

AU - Pro, Barbara

AU - Rodriguez, Maria A.

AU - Romaguera, Jorge E.

AU - Cabanillas, Fernando

AU - Rodriguez, Jose

AU - Cox, James D.

PY - 2002

Y1 - 2002

N2 - There is little information in the literature on outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. The purpose of this study was to analyze The University of Texas M.D. Anderson Cancer Center results in such patients. From 1985 to 1998, 39 patients with Stage I or II World Health Organization classification anaplastic large cell lymphoma (ALCL; n = 20), peripheral T-cell lymphoma, unspecified (PTCLu; n = 11), or nasal-type NK/T-cell lymphoma (NKTCL; n = 8) were treated using doxorubicin-based chemotherapy (median, 6 cycles) with (n = 24) or without (n = 15) radiotherapy (median dose, 40 Gy). Median age was 41 years. Median follow-up of surviving patients was 85 months. Even though patients who presented with bulky disease or who achieved less than a complete response to chemotherapy were the ones typically treated with combined modality therapy rather than chemotherapy alone, there was no significant difference in local control (5-year rates: 60 vs. 70%, p = 0.49), progression-free survival (5-year rates: 65 vs. 60%, p = 0.62), or overall survival (5-year rates: 74 vs. 67%, p = 0.47) between the groups treated with combined modality therapy and chemotherapy alone. Fifteen (38%) patients relapsed. Twelve relapses were limited to the initial site of disease; two involved the initial site and new sites, and one involved only new sites. Based on the significant risk of relapse at the initial site of disease, different approaches, including chemotherapy with concomitant radiotherapy to doses ≥45 Gy, warrant investigation.

AB - There is little information in the literature on outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. The purpose of this study was to analyze The University of Texas M.D. Anderson Cancer Center results in such patients. From 1985 to 1998, 39 patients with Stage I or II World Health Organization classification anaplastic large cell lymphoma (ALCL; n = 20), peripheral T-cell lymphoma, unspecified (PTCLu; n = 11), or nasal-type NK/T-cell lymphoma (NKTCL; n = 8) were treated using doxorubicin-based chemotherapy (median, 6 cycles) with (n = 24) or without (n = 15) radiotherapy (median dose, 40 Gy). Median age was 41 years. Median follow-up of surviving patients was 85 months. Even though patients who presented with bulky disease or who achieved less than a complete response to chemotherapy were the ones typically treated with combined modality therapy rather than chemotherapy alone, there was no significant difference in local control (5-year rates: 60 vs. 70%, p = 0.49), progression-free survival (5-year rates: 65 vs. 60%, p = 0.62), or overall survival (5-year rates: 74 vs. 67%, p = 0.47) between the groups treated with combined modality therapy and chemotherapy alone. Fifteen (38%) patients relapsed. Twelve relapses were limited to the initial site of disease; two involved the initial site and new sites, and one involved only new sites. Based on the significant risk of relapse at the initial site of disease, different approaches, including chemotherapy with concomitant radiotherapy to doses ≥45 Gy, warrant investigation.

KW - Chemotherapy

KW - Prognosis

KW - Radiotherapy

KW - T-cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=6444245388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6444245388&partnerID=8YFLogxK

U2 - 10.1080/1042819021000006277

DO - 10.1080/1042819021000006277

M3 - Article

C2 - 12685830

AN - SCOPUS:6444245388

VL - 43

SP - 1769

EP - 1775

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -